BTIG analyst Ryan Zimmerman downgraded RxSight (RXST) to Neutral from Buy without a price target The firm cites the “another quarter of weak” of preliminary results due to declining utilization and “extremely soft” Light Delivery Device sales for the downgrade. RxSight’s inability to navigate challenges along with a the need to readjust its sales processes suggests a drawn-out recovery, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXST:
- RxSight’s Strategic Initiatives and International Expansion Support Buy Rating Amidst Revenue Challenges
- RxSight downgraded to Equal Weight from Overweight at Wells Fargo
- Closing Bell Movers: AES Corp jumps 14% on takeover possibility
- RxSight cuts FY25 revenue view to $120M-$130M from $160M-$175M
- RxSight sees Q2 revenue $33.6M, consensus $39.78M